Die Infektion mit dem Humanen Immundefizienz-Virus (HIV) führt zu einer bedeutenden Erhöhung des kardiovaskulären Risikos. Im folgenden CME-Kurs erfahren Sie, warum das so ist, und welche therapeutischen Maßnahmen erforderlich sind, um HIV-Patienten möglichst optimal vor kardiovaskulären Ereignissen zu schützen.
Literatur
Palella FJ, Delaney KM, Moorman AC et al. Declining Morbidity and Mortality among Patients with Advanced Human Immunodefciency Virus Infection. New England Journal of Medicine. 1998;338:853–60.
Collaboration TATAC. HIV treatment response and prognosis in Europe and North America in the frst decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet. 2006;368(9534):451–8.
Samji H, Cescon A, Hogg RS et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.
Shah ASV, Stelzle D, Lee KK et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. Circulation. 2018;138:1100–12.
Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. Journal of the American Heart Association. 2019;8(14):e012241.
Feinstein MJ, Bahiru E, Achenbach C et al. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. The American Journal of Cardiology. 2016;117:214–20.
Marincowitz C, Genis A, Goswami N, De Boever P, Nawrot TS, Strijdom H. Vascular endothelial dysfunction in the wake of HIV and ART. The FEBS J. 2019;286:1256–70.
Calmy A, Gayet-Ageron A, Montecucco F et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929–39.
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodefciency virus infection and the acquired immunodefciency syndrome. 1992;74:1045–52.
Mujawar Z, Rose H, Morrow MP et al. Human Immunodefciency Virus Impairs Reverse Cholesterol Transport from Macrophages. PLoS Biology. 2006;4:e365.
Brath H, Grabovac I, Schalk H, Degen O, Dorner TE. Prevalence and Correlates of Smoking and Readiness to Quit Smoking in People Living with HIV in Austria and Germany. 2016;11:e0150553.
Rasmussen LD, Helleberg M, May MT et al. Myocardial Infarction Among Danish HIV-Infected Individuals: Population-Attributable Fractions Associated With Smoking. Clin Infect Dis. 2015;60:1415–23.
Helleberg M, Afzal S, Kronborg G et al. Mortality Attributable to Smoking Among HIV-1—Infected Individuals: A Nationwide, Population-Based Cohort Study. Clin Infect Dis. 2013;56:727–34.
Joy T, Keogh HM, Hadigan C et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. 2007;21(12):1591–1600.
Lai S, Fishman EK, Lai H et al. Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. Clin Infect Dis. 2008;46:600–10.
Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men. Clin Infect Dis. 2017;65:626–35.
Group TDCoAEoA-HDDS. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med. 2003;349:1993–2003.
Group TDS. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 2007;356:1723–35.
Kaplan RC, Kingsley LA, Sharrett AR et al. Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women. Clin Infect Dis. 2007;45:1074–81.
Stein JH, Hsue PY. Infammation, Immune Activation, and CVD Risk in Individuals With HIV Infection. JAMA. 2012;308:405.
Hadigan C, Meigs JB, Wilson PWF et al. Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution. Clin Infect Dis. 2003;36:909–16.
Worm SW, Friis-Møller N, Bruyand M et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different defnitions of the metabolic syndrome. AIDS. 2010;24:427–35.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodefciency Virus Disease. Clin Endocrinol Metab. 2007;92:2506–12.
Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
Group TSfMoATSS. CD4+ Count—Guided Interruption of Antiretroviral Treatment. N Engl J of Med. 2006;355:2283–96.
Marcus JL, Neugebauer RS, Leyden WA et al. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defc Syndr. 2016;71:413–9.
Strategies for Management of Anti-Retroviral Therapy I, Groups DADS. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24.
Panel EM. EACS Guidelines Version 10.0. Practice Guideline. 2019.
Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profle of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124:479–90.
Gallant JE, Daar ES, Raf F et al. Efcacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fxed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ. The Lancet HIV. 2016;3:e158–e165.
Wohl D, Oka S, Clumeck N et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defc Syndr. 2016;72:58–64.
Gebhardt A, Fichtenbaum CJ. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert Opin Pharmacother. 2019;20:1719–29.
Ryom L, Lundgren JD, El-Sadr W et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. The Lancet HIV. 2018;5:e291–e300.
Stein JH, Ribaudo HJ, Hodis HN et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29:1775–83.
Lafeur J, Bress AP, Rosenblatt L et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017;31:2095–106.
Tebas P, Sension M, Arribas J et al. Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1—Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials. Clin Infect Dis. 2014;59:425–34.
Molina J-M, Squires K, Sax PE et al. Doravirine versus ritonavirboosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, doubleblind, phase 3, non-inferiority trial. The Lancet HIV. 2018;5:e211–e220.
Ciaf L, Cavassini M, Genne D et al. Switch to etravirine for HIVpositive patients receiving statin treatment: a prospective study. Eur J Clin Invest. 2015;45:720–30.
Ofotokun I, Na LH, Landovitz RJ et al. Comparison of the Metabolic Efects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842–51.
Fung HB, Guo Y. Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther. 2004;26:352–78.
Daar ES, Dejesus E, Ruane P et al. Efcacy and safety of switching to fxed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph. The Lancet HIV. 2018;5:e347–e356.
Martínez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
Gatell JM, Assoumou L, Moyle G et al. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor—based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. Clin Infect Dis. 2019;68:597–606.
Bourgi K, Rebeiro PF, Turner M et al. Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy. Clin Infect Dis. 2020;70:1267–74.
Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. Top HIV Med. 2010;18:112–8.
Macinnes A, Lazzarin A, Di Perri G et al. Maraviroc Can Improve Lipid Profles in Dyslipidemic Patients with HIV: Results from the MERIT Trial. HIV Clin Trials. 2011;12:24–36.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifcation to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1–10.
Zanetti HR, Gonçalves A, Teixeira Paranhos Lopes L et al. Efects of Exercise Training and Statin Use in People Living with Human Immunodefciency Virus with Dyslipidemia. Medicine and science in sports and exercise. Med Sci Sports Exerc. 2020;52:16–24.
Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodefciency Virus Type 1—Infected Individuals. J Am Coll Cardiol. 2012;59:979–88.
Gutierrez MDM, Mateo MG, Corbacho N, Vidal F, Domingo P. Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology. 2019:1–16.
Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Efect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defc Syndr. 2005;39:307–12.
Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. Clin Pharmacokinet. 2011 Jan;50:25–39.
Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Clin Infect Dis. 2015; 61: 1566–72.
Khalilieh S, Yee KL, Sanchez RI et al. Results of a doravirineatorvastatin drug-drug interaction study. 2016:AAC.01364–01316.
van Luin M, Colbers A, van Ewijk-Beneken Kolmer EWJ et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defc Syndr. 2010;55:82–6.
Negredo E, Moltó J, Puig J et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006;20(17):2159–64.
Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109c.
Feinstein MJ, Hsue PY, Benjamin LA et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientifc Statement From the American Heart Association. Circulation. 2019;140(2):e98–e124.
Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population. Ann Pharmacother. 2011;45:1230–9.
Longenecker CT et al. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29:1–9
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of a supplement not sponsored by the industry.
Interessenkonflikt
Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: ..... (z.B. keine) Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.
Rights and permissions
About this article
Cite this article
Hollstein, T., Schumann, F. & Kassner, U. HIV-Infektion und Lipidentgleisung — Gründe und Gegenmaßnahmen. MMW - Fortschritte der Medizin 162 (Suppl 2), 54–61 (2020). https://doi.org/10.1007/s15006-020-0015-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-020-0015-9